Country Concert for Cystic Fibrosis

Gilead Sciences, Inc. (Nasdaq:GILD) announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Cayston(R)(aztreonam for inhalation solution) as a treatment to improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa (P. aeruginosa)...

Country Concert for Cystic Fibrosis

Aradigm Corporation (OTCBB:ARDM) (the "Company") announced that it dosed the first patient in the U.S...

Country Concert for Cystic Fibrosis

We have a new antibiotic in the arsenal to help fight the life-threatening infections associated with cystic fibrosis.

Yesterday, the FDA approved an important new inhaled antibiotic called Cayston^® (aztreonam for inhalation solution) for the treatment of CF. The drug was made possible by significant support from the Cystic Fibrosis Foundation, including an early $1 million investment to help develop the therapy.

Developed by Gilead Sciences, Inc., Cayston offers a much-needed antibiotic alternative for CF patients who battle recurrent lung infections and develop resistance to existing antibiotics.

Cayston is administered with a new device called Altera that allows patients to take the medicine in less than five minutes, a fraction of the time required for other inhaled antibiotics.

This shortened delivery time reduces the burden on patients, who – on average — have a treatment regimen of three to four hours per day.

Cayston will be available by the end of next week. Patients interested in learning more about Cayston should consult their physicians.

The approval of Cayston demonstrates that our drug development model, fueled by donors and volunteers like you, is working and making a real difference in the lives of people with cystic fibrosis.

To help continue our progress in the fight against CF, please consider making a tax-deductible donation to the CF Foundation today.

Thank you for all you do.

Sincerely,

Robert J. Beall, Ph.D.
President and CEO
Cystic Fibrosis Foundation
800-FIGHT-CF
info@cff.org
www.cff.org

Country Concert for Cystic Fibrosis

Third Annual Cystic Fibrosis Country Concert

Please Save the Date for the 3rd Annual CF Concert & Motorcycle Ride on Sunday AUG 22,2010 at the American Legion Post 781 Grounds in Mountain Top,Pa (approx 1mile off of the Nuangola Exit on 81 or 3 miles from RT 309)… Concert Starting at 1pm.. General Admission to CONCERT only $5.00 Donation/Children under 12 FREE.. In addition to the GREAT BANDS, the Concert will also feature:

• the National Guard, Nascar
• a Classic Car Show Sponsord by RACE Car club
• Messages by McCain School of Mesages
• Free Petting Zoo for the kids
• Basket Raffles/Tricky Trays
• Good Food at Reasonable Prices
• Great Sponsors & vendors with free giveaways…

Beer,Soda & Water only $1.00…So much to do we can’t fit it on the page CONCERT WILL FEATURE an Up CLose and Personal Concert Sponsored by FROGGY 101

Farmer's Daughter
Crystal Martinez	Big Carl & the Mudpond Boys

…and more to be added in the next few weeks.

MOTOR CYCLE RIDE INFO:

$20 per person per RIDER..

$10 per person for PASS

Both include a delicious PIG ROAST LUNCH at conclusion of ride at the American Legion MT Top… Sign-In starts at 9:30am -11:30 at the KMART parking lot on RT 309 WB.. Donuts, coffee and water provided by Dunkin Donuts WB/& Paiges Family… Ride leaves promptly from KMART parking lot at 11:30 with a 65 mile ride that will go 309 to 437 through Freeland and the Conyingham Valley and the ride concludes at the American Legion Post 781 where your lunch and a great day awaits you… First 200 to arrive at legion will also recieve Thank you bags…

Hope To See You There!

Country Concert for Cystic Fibrosis

As prenatal and embryonic genetic testing has become more widespread in the U.S., the number of infants with certain inheritable diseases -- such as cystic fibrosis, Tay-Sachs and familial dysautonomia -- has declined, according to an Associated Press review of research and interviews with genetics experts, the AP/Seattle Times reports...

Country Concert for Cystic Fibrosis

An inexpensive, fast, accurate DNA test that reveals a person's risk of developing certain diseases is expected to become a reality, thanks to technology developed at the University of Edinburgh. Scientists have developed a method of pinpointing variations in a person's genetic code at critical points along the DNA chain. The technique could be used to analyse DNA in a drop of saliva...

Country Concert for Cystic Fibrosis

In a study that could lead to new therapeutic targets for patients with the cystic fibrosis, a research team from the University of California, San Diego School of Medicine has identified a defective signaling pathway that contributes to disease severity...

As you may know, last week we announced encouraging results from Vertex Pharmaceuticals Incorporated‘s Phase 2a trial of VX-809, one of the first investigational drugs aimed at treating the underlying causes of cystic fibrosis. Learn more about this exciting advancement.The remarkable progress of VX-809 is a reminder of why it is so important to remove barriers that prevent people with CF from participating in clinical trials. Passing the “Improving Access to Clinical Trials Act of 2009” will allow people with CF who are on public benefits to participate in important research without losing their health coverage. We continue to work with Congressional supporters to chart the best path forward for the bill. There are two options to pass the bill:

Option #1: On its own

Non-controversial, bi-partisan and no-cost legislation like the clinical trials bill may be considered under special procedural rules. Thanks to your hard work, 110 members of the House, and eight members of the Senate have signed on as co-sponsors, meeting the requirements to provide the bill the opportunity to advance on its own.

Option #2: As part of a health care reform bill

Despite the shift away from health reform in past weeks, our sponsors – several of whom are key negotiators on health reform – continue to consider it as an option and the best opportunity to move the bill sooner rather than later.

Read more about what H.R. 2866 would do.

What You Can Do Today

The bill has two viable opportunities because you made it clear to your members of Congress that this is a priority for you and should be for them as well.

Ask your members of Congress to keep the “Improving Access to Clinical Trials Act” on their agenda until it passes.

Looking to do more to help fight CF? Sign up for a GREAT STRIDES walk!This spring, take steps to cure cystic fibrosis by signing up for a GREAT STRIDES walk. Join tens of thousands of co-workers, friends and family come together each year as one community for one cause…to help find a cure for CF. In 2009, nearly $35 million was raised to support vital CF programs. Register online today!

Thank you for your support!

Mary B. Dwight
Vice President for Government Affairs
Cystic Fibrosis Foundation
(800) FIGHT CF
publicpolicy@cff.org

MAKE AN IMPACT ON CF

SPEAK OUT
Get Started

GET INVOLVED
Sign up

INSPIRE ACTION
Recruit friends and family

————————-
To learn more about the Cystic Fibrosis Foundation, visit www.cff.org.

Country Concert for Cystic Fibrosis

As part of a steadfast commitment to finding a cure for cystic fibrosis, BJ's Restaurants, Inc. donated $521,000 to the Cystic Fibrosis Foundation in 2009 for research, care and education programs. BJ's has been involved with the Foundation since 1998 and is one of its largest and most loyal corporate supporters...

Country Concert for Cystic Fibrosis

Solvay Pharmaceuticals, Inc...

This week, we gained important new ground in our work to advance the development of new cystic fibrosis treatments.

VX-809, a potential CF drug developed by Vertex Pharmaceuticals, showed encouraging results in a preliminary Phase 2a clinical trial.  VX-809 is one of the first investigational drugs aimed at treating the underlying causes of CF.

The oral therapy was tested in patient volunteers who have the most common cystic fibrosis mutation, Delta F508.

Results from the trial showed VX-809 was well-tolerated and, in a subset of CF patients, reduced sweat chloride levels ? a key indicator of CF.

VX-809 is the direct result of one of the Foundation?s largest investments in drug development.  This gives us confidence that our innovative approach to science leads to progress.

Learn more about this study.

Without your support, this milestone would simply not be possible.  Your contributions help us build hope for the future and continue to advance vital cystic fibrosis research.

If you have CF, you can also help by participating in a clinical trial. Visit the Foundation?s Web site to learn more about clinical trials and to find out how you can get involved.

Thank you for your commitment to the fight against CF. Together, we are making a difference!